CDKN2/p16 inactivation and p16 immunohistochemistry in astrocytic gliomas

International Journal of Oncology

Volumn 12, Issue 1, 1998, Pages 55-58

  Piva, Roberto ^a   Cavalla, Paola ^a   Bortolotto, Simona ^a   Cordera, Susanna ^a   Grosso, Roberta ^a   Richiardi, Paola ^a   Dutto, Anna ^a   Schiffer, Davide ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

CDKN2 p16 homozygous deletion; Gliomas; MIB 1; p16 immunohistochemistry

Indexed keywords

PROTEIN P16; DNA; KI 67 ANTIGEN; PRIMER DNA; PROTEIN P16INK4A;

ADULT; ARTICLE; ASTROCYTOMA; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CLINICAL ARTICLE; FEMALE; GENE DELETION; GENOTYPE; GROWTH REGULATION; HOMOZYGOSITY; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MOLECULAR RECOGNITION; PRIORITY JOURNAL; TUMOR GROWTH; BRAIN TUMOR; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; GENETICS; METABOLISM; MIDDLE AGED; POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE;

ASTROCYTOMA; BRAIN NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA PRIMERS; DNA, NEOPLASM; FEMALE; GENE DELETION; GENES, P16; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION;

EID: 0031974175     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.12.1.55     Document Type: Article

References (21)

1. INK4/CDKN2 and cyclin D1 cooperate to deregulate Gl control. Cancer Res 55: 4818-4823, 1995.
2. Louis DN: A molecular genetic model of astrocytoma histopathology. Brain Pathol 7: 755-764, 1997.
3. Giani C and Finocchiaro G: Mutation rate of CDKN2 gene in malignant gliomas. Cancer Res 54: 6338-6339, 1994.
4. Jen J, Harper W, Bigner SH, Bigner DD, Papadopoulos N, Markowitz S, Willson JKV, Kinzler KW and Vogelstein B: Deletion of p16 and p15 genes in brain tumors. Cancer Res 54: 6353-6358, 1994.
5. Schmidt EE, Ichimura K, Reifenberger G and Collins VP: CDKN2(p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 54: 6321-6324, 1994.
6. Moulton T, Samara G, Chung W-Y, Yuan L, Desai R, Sisti M, Bruce J and Tycko B: MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme. Am J Pathol 146: 613-619, 1995.
7. Walker DG, Duan W, Popovic EA, Kaye AH, Tomlinson FH and Lavin M: Homozygous deletions of the multiple tumor suppressor gene 1 in the progression of human astrocytomas. Cancer Res 55: 20-23, 1995.
8. Ueki K, Ono Y, Henson JW, Efird JT, von Deimling A and Louis DN: CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 56: 150-153, 1996.
9. Dreyling MH, Bohlander SK, Adeyanju MO and Olopade OI: Detection of CDKN2 deletions in tumor cell lines and primary glioma by interphase fluorescence in situ hybridization. Cancer Res 55: 984-988, 1995.
10. Ueki K, Rubio MP, Ramesh V, Correa KM, Rutter JL, von Deimling A, Buckler AJ, Gusella JF and Louis DN: MTS1/CDKN2 gene mutations are rare in primary human astrocytomas with allelic loss of chromosome 9p. Hum Mol Genet 3: 1841-1845, 1994.
11. Costello JF, Berger MS, Su Huang H-J and Cavenee WK: Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. Cancer Res 56: 2405-2410, 1996.
12. Ono Y, Tamiya T, Ichikawa T, Kunishio K, Matsumoto K, Furuta T, Ohmoto T, Ueki K and Louis DN: Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have higher Ki-67 proliferation indeces. J Neuropathol Exp Neurol 55: 1026-1031, 1996.
13. INK4A genes in astrocytomas. Diagn Mol Pathol 6: 115-122, 1997.
14. Kleihues P, Burger PC and Scheithauer BW: Histological typing of tumours of the central nervous system. Springer, Berlin, 1993.
15. Coons SW and Johnson PC: Regional heterogeneity in the proliferative activity of human gliomas as measured by the Ki-67 labelling index. J Neuropathol Exp Neurol 52: 609-618, 1993.
16. INK4 expression is frequent in high grade gliomas. Cancer Res 55: 1941-1945, 1995.
17. Schiffer D, Cavalla P, Pilkington GJ: Proliferative properties of malignant brain tumors. In: Brain Tumor Invasion, Biological, Clinical and Therapeutic considerations. Mikkelsen T, Bjerkvig R, Laerum O, Rosenblum ML (eds.) Wiley and Sons, Chichester (In press).
18. Merlo A, Herman JG, Mao L, et al: 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1. Nat Med 1: 686-692, 1995.
19. Lloyd RV, Jin L, Qian X and Kulig E: Aberrant p27/kip1 expression in endocrine and other tumors. Am J Pathol 150: 401-407, 1997.
20. Piva R, Cavalla P, Bortolotto S, Cordera S, Richiardi P and Schiffer D: p27/kip1 expression in human astrocytic gliomas. Neurosci Lett 234: 127-130, 1997.
21. Perry A, Nobori T, Ru N, Anderl K, Borell TJ, Mohapatra G, Feuerstein BG, Jenkins RB and Carson DA: Detection of p16 gene deletions in gliomas: a comparison of fluorescence in situ hybridization (FISH) versus quantitative PCR. J Neuropathol Exp Neurol 56: 999-1008, 1997.